Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

ABSTRACT:

SUBMITTER: van der Wekken AJ 

PROVIDER: S-EPMC6072953 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature